biotech · Advanced Solid Tumor · Sjogren's Disease · CGEM
Cullinan Therapeutics
Cullinan Therapeutics patent portfolio — 3 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Dyer St, Providence, Rhode Island 02903, US HQ
2017 Founded
7 Employees
Public company Type
CGEM · NYSE Ticker
Company details
- Status
- Public
- HQ
- Dyer St, Providence, Rhode Island 02903, US
- Founded
- 2017
- Employees
- 7
- Programs
- 16
- Drugs
- 14
- Patents
- 3
Cullinan Therapeutics patents
3 pharmaceutical patents indexed for Cullinan Therapeutics. 0 expire within 24 months.
Cullinan Therapeutics has 3 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
Frequently asked questions
How many patents does Cullinan Therapeutics have?
3 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Cullinan Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.